The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures
暂无分享,去创建一个
[1] E. Coppin,et al. Flow cytometric analysis of intracellular phosphoproteins in human monocytes , 2017, Cytometry. Part B, Clinical cytometry.
[2] E. Petricoin,et al. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors , 2015, Oncotarget.
[3] M. Masuda,et al. Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine. , 2015, Biochimica et biophysica acta.
[4] T. Mukohara,et al. PI3K mutations in breast cancer: prognostic and therapeutic implications , 2015, Breast cancer.
[5] K. Darwiche,et al. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. , 2015, Lung cancer.
[6] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[7] Jin-Ling Tang,et al. The prognostic value of phosphorylated Akt in breast cancer: a systematic review , 2015, Scientific Reports.
[8] Jean J. Zhao,et al. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.
[9] M. Ando,et al. Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Zhi-qin Fu,et al. Prognostic value of phospho‐Akt in patients with non‐small cell lung carcinoma: A meta‐analysis , 2014, International journal of cancer.
[11] E. Petricoin,et al. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer , 2014, Breast Cancer Research and Treatment.
[12] K. Zhao,et al. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer. , 2014, Current medicinal chemistry.
[13] C. Cui,et al. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma , 2014, BMC Cancer.
[14] E. Petricoin,et al. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. , 2014, Journal of proteome research.
[15] Jiri Polivka,et al. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, Pharmacology & therapeutics.
[16] Jing Cai,et al. The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis. , 2014, The oncologist.
[17] A. Pandiella,et al. Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis , 2014, PloS one.
[18] R. O'Regan,et al. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers , 2014, Therapeutic advances in medical oncology.
[19] G. Lazaridis,et al. Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer , 2014, Strahlentherapie und Onkologie.
[20] H. Höfler,et al. Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer , 2014, British Journal of Cancer.
[21] Emanuel F Petricoin,et al. Preparation and Use of Reverse Protein Microarrays , 2014, Current protocols in protein science.
[22] C. Rommel,et al. PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.
[23] Z. Qiu,et al. The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: A Meta-Analysis , 2013, PloS one.
[24] T. Petit,et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study , 2013, Targeted Oncology.
[25] S. Vacher,et al. PIK3R1 underexpression is an independent prognostic marker in breast cancer , 2013, BMC Cancer.
[26] D. Sgroi,et al. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials , 2013, Breast Cancer Research.
[27] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[28] Jun Li,et al. TCPA: a resource for cancer functional proteomics data , 2013, Nature Methods.
[29] E. Petricoin,et al. Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations , 2013, Clinical & Experimental Metastasis.
[30] P. V. van Diest,et al. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment , 2012, Breast Cancer Research.
[31] L. Skoog,et al. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit , 2012, Breast Cancer Research and Treatment.
[32] E. Petricoin,et al. Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping , 2012, Clinical Cancer Research.
[33] Ronald J. Moore,et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum , 2012, Proceedings of the National Academy of Sciences.
[34] Brett Houser,et al. Bio-Rad’s Bio-Plex® suspension array system, xMAP technology overview , 2012, Archives of physiology and biochemistry.
[35] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[36] H. Kluger,et al. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer , 2011, Journal of Translational Medicine.
[37] J. Blenis,et al. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.
[38] Hyun-Ah Kim,et al. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer , 2011, Breast Cancer Research and Treatment.
[39] Walter Kolch,et al. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer , 2010, Nature Reviews Cancer.
[40] Lei Jin,et al. Development and application of ‘phosphoflow’ as a tool for immunomonitoring , 2010, Expert review of vaccines.
[41] M. Duffy,et al. Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib , 2010, Molecular Cancer Therapeutics.
[42] J. Engelman,et al. The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Qin Fu,et al. Comparison of multiplex immunoassay platforms. , 2010, Clinical chemistry.
[44] K. Cederbrant,et al. Meso Scale Discovery and Luminex Comparative Analysis of Calbindin D28K , 2009, Journal of biomedicine & biotechnology.
[45] P. Auclair,et al. Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study , 2009, BMC Cancer.
[46] J. Nunès,et al. Analysis of Signaling Events by Dynamic Phosphoflow Cytometry , 2009, Science Signaling.
[47] Jeffrey A. Engelman,et al. Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.
[48] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[49] Xu Shi,et al. Quantification of Cardiovascular Biomarkers in Patient Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution* , 2009, Molecular & Cellular Proteomics.
[50] R. Aebersold,et al. Selected reaction monitoring for quantitative proteomics: a tutorial , 2008, Molecular systems biology.
[51] Pier Paolo Pandolfi,et al. The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.
[52] M. Mann,et al. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. , 2008, Molecular cell.
[53] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[54] Bert Vogelstein,et al. The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.
[55] L. Liotta,et al. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine , 2007, Expert review of molecular diagnostics.
[56] P. Workman,et al. Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts. , 2007, Assay and drug development technologies.
[57] Yuval Inbar,et al. Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit , 2007, Science.
[58] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[59] Garry P Nolan,et al. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling , 2006, Nature Methods.
[60] W. de Jager,et al. Solid-phase and bead-based cytokine immunoassay: a comparison. , 2006, Methods.
[61] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[62] M. Loda,et al. The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .
[63] J. Engelman,et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. , 2005, Cancer research.
[64] J. Bartlett,et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen , 2005, The Journal of pathology.
[65] M. Berger,et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.
[66] J. Coon,et al. EGFR mutations and pAKT expression as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC) patients (pts) , 2005 .
[67] Elisa Rossi,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[68] K. O'Byrne,et al. Phospho-Akt Expression Is Associated with a Favorable Outcome in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[69] S. Hirohashi,et al. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma , 2005, Cancer.
[70] F. Cappuzzo,et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. , 2004, Journal of the National Cancer Institute.
[71] M. Paul,et al. Tyrosine kinase – Role and significance in Cancer , 2004, International journal of medical sciences.
[72] H. Lee,et al. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[73] M. White,et al. c-Jun N-terminal Kinase (JNK) Mediates Feedback Inhibition of the Insulin Signaling Cascade* , 2003, The Journal of Biological Chemistry.
[74] D. Rimm,et al. Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.
[75] P. Dennis,et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.
[76] E. Petricoin,et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.
[77] Michael J. Fry,et al. Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.
[78] James V. Watson,et al. Introduction to Flow Cytometry , 1991 .
[79] L. Huber,et al. Mapping in vivo signal transduction defects by phosphoproteomics. , 2012, Trends in molecular medicine.